<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00814229</url>
  </required_header>
  <id_info>
    <org_study_id>UHL 08162</org_study_id>
    <secondary_id>REC 6794</secondary_id>
    <nct_id>NCT00814229</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of Influenza H9 Vaccine in Humans</brief_title>
  <official_title>Randomised Dose Ranging Observer Blind Single Centre Study to Evaluate Safety and Immunogenicity of Adjuvanted and Non-adjuvanted Influenza H9 Influenza Vaccine in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospitals, Leicester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Crucell Holland BV</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Biological Standards and Control</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Public Health England</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospitals, Leicester</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      H9N2 influenza circulates in animal and poultry and has caused delf limiting infections in&#xD;
      children. Influenza H9N2 poses a pandemic threat to humans.&#xD;
&#xD;
      This study evaluates the safety and immunogenicity of adjuvanted and non-adjuvanted whole&#xD;
      virus and virosomal H9N2 vaccines by the intramuscular route. We also assess intradermal&#xD;
      route of administration to see if this has any advantages. The aim is to assess antibody&#xD;
      responses before and after vaccination. The hypothesis is that lower doses of adjuvanted&#xD;
      vaccine will induce similar antibody responses to non-adjuvanted vaccine&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A double-blind, single centre comparative study in which fourteen groups of 40 male and&#xD;
      female adults &gt;18 years of age will be randomly allocated to receive 1.7, 5, 15 or 45 Âµg&#xD;
      quantities of whole virion (WV), Aluminium -adjuvanted WV(Al-WV), and virosomal (V) influenza&#xD;
      A/Hong Kong/1073/99 (H9N2) vaccines by intramuscular injection into the deltoid muscle; or 5&#xD;
      or 15microg WV vaccine administered by intradermal injection. A second dose of the same&#xD;
      vaccine containing the same quantity of antigen as in the first dose will be administered 21&#xD;
      days later. Subjects will be observed for local and systemic reactions for 30 minutes after&#xD;
      each immunisation (day 0 and 21), and will be monitored for any reactions and other adverse&#xD;
      events for 7 days after immunisation. Blood for immunogenicity studies will be obtained at&#xD;
      day 0 (pre-immunisation), day-21 (+4 days), and at day-42 (i.e., 21 +4 days after the second&#xD;
      immunization). Immunogenicity will be evaluated by haemagglutination inhibition, virus&#xD;
      neutralization,, single radial haemolysis, neuraminidase inhibition and cellular mediated&#xD;
      responses (in a subset of 5-10 subjects from each group).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric mean antibody titres of antibody to influenza H9 by HI and neutralising antibody assays</measure>
    <time_frame>Pre vaccination, 21 days and 42 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local and systemic reactogenicity of influenza H9 vaccine</measure>
    <time_frame>within 7 days of vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>seroprotective antibody titres to influenza H9 by HI and neutralising antibody</measure>
    <time_frame>pre vacciantion, 21 and 42 days post-vaccine</time_frame>
  </secondary_outcome>
  <number_of_arms>14</number_of_arms>
  <enrollment type="Actual">353</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Vaccine 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>influenza H9N2 vaccine whole virus containing 1.5microg haemagglutinin by intramuscular injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>vaccine 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>influenza H9N2 vaccine whole virus containing 5microg haemagglutinin by intramuscular injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaccine 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>influenza H9N2 vaccine whole virus containing 15microg haemagglutinin by intramuscular injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaccine 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>influenza H9N2 vaccine whole virus containing 45microg haemagglutinin by intramuscular injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaccine 5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 1.5microg haemagglutinin by intramuscular injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaccine 6</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 5microg haemagglutinin by intramuscular injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaccine 7</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 15microg haemagglutinin by intramuscular injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaccine 8</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 45microg haemagglutinin by intramuscular injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaccine 9</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>influenza H9N2 vaccine virosomal containing 1.5microg haemagglutinin by intramuscular injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaccine 10</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>influenza H9N2 vaccine virosomal containing 5microg haemagglutinin by intramuscular injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaccine 11</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>influenza H9N2 vaccine virosomal containing 15microg haemagglutinin by intramuscular injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaccine 12</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>influenza H9N2 vaccine virosomal containing 45microg haemagglutinin by intramuscular injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaccine 13</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>influenza H9N2 vaccine whole virus containing 5microg haemagglutinin by intradermal injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaccine 14</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>influenza H9N2 vaccine whole virus containing 15microg haemagglutinin by intradermal injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>H9N2 whole virus vaccine, IM, 1.5microg</intervention_name>
    <description>influenza H9N2 vaccine whole virus containing 1.5microg haemagglutinin by intramuscular injection</description>
    <arm_group_label>Vaccine 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>H9N2 whole virus vaccine, IM, 5microg</intervention_name>
    <description>influenza H9N2 vaccine whole virus containing 5microg haemagglutinin by intramuscular injection</description>
    <arm_group_label>vaccine 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>H9N2 whole virus vaccine vaccine, IM, 15microg</intervention_name>
    <description>influenza H9N2 vaccine whole virus containing 15microg haemagglutinin by intramuscular injection</description>
    <arm_group_label>Vaccine 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>H9N2 whole virus vaccine, IM, 45microg</intervention_name>
    <description>influenza H9N2 vaccine whole virus containing 45microg haemagglutinin by intramuscular injection</description>
    <arm_group_label>Vaccine 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>H9N2 whole virus vaccine, alum, IM, 1.5microg</intervention_name>
    <description>influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 1.5microg haemagglutinin by intramuscular injection</description>
    <arm_group_label>Vaccine 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>H9N2 whole virus, alum, IM, 5microg</intervention_name>
    <description>influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 5microg haemagglutinin by intramuscular injection</description>
    <arm_group_label>Vaccine 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>H9N2 vaccine, whole virus, alum, IM, 15 microg</intervention_name>
    <description>influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 15microg haemagglutinin by intramuscular injection</description>
    <arm_group_label>Vaccine 7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>H9N2 vaccine, whole virus, alum, IM, 45microg</intervention_name>
    <description>influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 45microg haemagglutinin by intramuscular injection</description>
    <arm_group_label>Vaccine 8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>H9N2 virosome vaccine, IM, 1.5microg</intervention_name>
    <description>influenza H9N2 vaccine virosomal containing 1.5microg haemagglutinin by intramuscular injection</description>
    <arm_group_label>Vaccine 9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>H9N2 virosomal vaccine, IM, 5microg</intervention_name>
    <description>influenza H9N2 vaccine virosome containing 5microg haemagglutinin by intramuscular injection</description>
    <arm_group_label>Vaccine 10</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>H9N2 virosomal vaccine, IM, 15microg</intervention_name>
    <description>influenza H9N2 vaccine virosome containing 15microg haemagglutinin by intramuscular injection</description>
    <arm_group_label>Vaccine 11</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>H9N2 virosomal vaccine, IM, 45microg</intervention_name>
    <description>influenza H9N2 vaccine virosome containing 45microg haemagglutinin by intramuscular injection</description>
    <arm_group_label>Vaccine 12</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>H9N2 whole virus vaccine, ID, 5microg</intervention_name>
    <description>influenza H9N2 vaccine whole virus containing 5microg haemagglutinin by intradermal injection</description>
    <arm_group_label>Vaccine 13</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>H9N2 whole virus vaccine, ID, 15microg</intervention_name>
    <description>influenza H9N2 vaccine whole virus containing 15microg haemagglutinin by intradermal injection</description>
    <arm_group_label>Vaccine 14</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Mentally competent adults, who have signed an informed consent form after having&#xD;
             received a detailed explanation of the study protocol.&#xD;
&#xD;
          -  Male or female subjects over 18 years who are either healthy or have a stable medical&#xD;
             condition.&#xD;
&#xD;
          -  Able to understand and comply with all study procedures and to complete study diaries&#xD;
&#xD;
          -  Individuals who can be contacted throughout the study and are available for all study&#xD;
             visits&#xD;
&#xD;
          -  Females should either be using secure contraceptive precautions including a) the oral&#xD;
             contraceptive pill, b) condom/barrier contraception c) partner has had a vasectomy, d)&#xD;
             be surgically sterilised, or e) post- (defined as at least two years since the last&#xD;
             menstrual period)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any clinically significant concurrent illness or unstable medical condition including:&#xD;
             malignant tumours, autoimmune illnesses (including rheumatoid arthritis), acute or&#xD;
             progressive renal or hepatic pathology, chronic obstructive pulmonary disease&#xD;
             requiring oxygen therapy, and any active neurological disorder.&#xD;
&#xD;
          -  Individuals with a history of anaphylaxis or serious reactions to vaccines;&#xD;
             hypersensitivity to eggs, chicken protein, chicken feathers, influenzal viral protein,&#xD;
             neomycin or polymixin, or products containing mercury.&#xD;
&#xD;
          -  Persons with known immunosuppressive disease or who use systemic immunosuppressive&#xD;
             drugs or other drugs listed in section 8 of the British National Formulary (BNF) or&#xD;
             chloroquine, gold or penicillamine or other drugs listed in section 10.1.3 of the BNF&#xD;
             to suppress a chronic disease process, or have received in the last 6 months&#xD;
             radiotherapy or chemotherapy.&#xD;
&#xD;
          -  Subjects who are at high risk of developing illnesses of the immune system.&#xD;
&#xD;
          -  Individuals who are taking immunostimulant therapy or interferon&#xD;
&#xD;
          -  Individuals who have received blood products or immunoglobulins parenterally during&#xD;
             the preceding three months.&#xD;
&#xD;
          -  Women should not be pregnant or lactating.&#xD;
&#xD;
          -  Women who refuse to use a reliable contraceptive method throughout the study&#xD;
&#xD;
          -  Known or suspected drug abuse.&#xD;
&#xD;
          -  Individuals who have received another vaccine or experimental (investigational) drug&#xD;
             in the preceding 4 weeks.&#xD;
&#xD;
          -  Individuals who have previously received H9N2 vaccine&#xD;
&#xD;
          -  Unable to lead an independent life either physically or mentally&#xD;
&#xD;
          -  Regularly drink more than 40 units of alcohol weekly&#xD;
&#xD;
          -  Individuals who have had acute respiratory pathology or infections requiring systemic&#xD;
             antibiotic or antiviral therapy during the preceding 7 days (chronic antibiotic&#xD;
             therapy for prevention of urinary tract infections is acceptable).&#xD;
&#xD;
          -  Individuals who had a temperature over 38 degrees C in the preceding 3 days.&#xD;
&#xD;
          -  Individuals who, in the opinion of the investigator, have conditions that might&#xD;
             complicate interpretation of the study results.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karl G Nicholson, FRCP, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Leicester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospitals Leicester</name>
      <address>
        <city>Leicester</city>
        <state>Leicestershire</state>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <study_first_submitted>December 23, 2008</study_first_submitted>
  <study_first_submitted_qc>December 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2008</study_first_posted>
  <last_update_submitted>July 20, 2009</last_update_submitted>
  <last_update_submitted_qc>July 20, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 21, 2009</last_update_posted>
  <responsible_party>
    <name_title>Profressor Karl Nicholson</name_title>
    <organization>University of Leicester</organization>
  </responsible_party>
  <keyword>influenza</keyword>
  <keyword>H9N2</keyword>
  <keyword>vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Aluminum sulfate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

